利用人工智能挖掘肿瘤及周围组织信息预测肺癌对EGFR靶向治疗和免疫治疗的应答:一项多中心归因分析
本研究整合中国和美国三个机构506例非小细胞肺癌患者数据,构建基于注意力DenseNet 121骨干网络的整合人工智能框架(IFAI),融合肿瘤及周围组织的影像组学评分与深度网络特征。在独立测试集中,IFAI联合临床因素(IFAI-C)预测EGFR、19Del、L858R、T790M及PD-1/PD-L1的AUC分别为0.912、0.911、0.905、0.911和0.904。RNA测序分析显示IFAI特征与EGFR基因型、耐药突变及免疫分子表达显著相关。
要点
- IFAI-C在独立测试集中预测EGFR的AUC为0.912,预测19Del的AUC为0.911。
- IFAI-C预测L858R、T790M及PD-1/PD-L1的AUC分别为0.905、0.911和0.904。
- IFAI中影像组学评分和深度网络特征与EGFR基因型、耐药突变及免疫分子表达显著相关。
核心结论
- IFAI-C提出一种具有性能优势的新方法,生物学分析表明可从肿瘤及周围组织中提取基因型和免疫分子信息,这一发现对指导肺癌治疗决策具有潜在价值。
研究设计与样本
- 多中心归因分析,整合中国和美国三个机构506例非小细胞肺癌患者数据,以基于注意力的DenseNet 121为骨干网络开发IFAI,融合肿瘤及周围组织的影像组学评分与深度网络特征,并探索IFAI与临床因素的协同(IFAI-C),同时分析患者RNA测序数据。
诊断标准与关键数值
- 独立测试集中IFAI-C预测EGFR的AUC为0.912,预测外显子19缺失(19Del)的AUC为0.911,预测外显子21突变(L858R)的AUC为0.905,预测T790M的AUC为0.911,预测程序性死亡蛋白1(PD-1)或其配体1(PD-L1)的AUC为0.904。
临床应用与阅片要点
- IFAI-C是传统基因测序和免疫组化方法的重要补充,作者认为该发现对指导肺癌治疗决策具有潜在价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: In cancer therapy, tumor cell heterogeneity and dynamics influence gene sequencing and immunohistochemical staining. Importantly, patients treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have not demonstrated a favorable long-term prognosis. Therefore, this study proposes an integrated framework for artificial intelligence (IFAI) to explore new molecular detection methods.
MATERIALS AND METHODS: Our study integrated data from 506 non-small cell lung cancer (NSCLC) patients across three institutions in China and the USA. To fuse radiomics scores and deep network features from both tumors and surrounding tissues, we developed the IFAI with an attention-based DenseNet 121 as the backbone network. We also explored the synergy between IFAI and clinical factors (IFAI-C). Additionally, we gained further insights into the biological mechanisms of IFAI by analyzing patient RNA sequencing data.
RESULTS: In independent test data, the IFAI-C demonstrated notable predictive performance, boasting an area under the curve of 0.912 for EGFR, 0.911 for exon 19 deletion (19Del), 0.905 for exon 21 mutation (L858R), 0.911 for T790M, and 0.904 for programmed cell death protein 1 (PD-1) or its ligand 1 (PD-L1). This capability is a crucial complement to traditional methods like gene sequencing and immunohistochemistry. Our analysis revealed that radiomics scores and deep network features in IFAI were significantly associated with EGFR genotypes, drug resistance mutations, and immune molecule expression. Furthermore, these features displayed robust connections with multiple genotypes associated with drug resistance and cancer progression mechanisms.
CONCLUSION: IFAI-C introduces a novel method with performance advantages, accompanied by biological analyses demonstrating the extraction of genotypic and immunomolecular information from both tumors and surrounding tissues. This discovery holds potential value in guiding therapeutic decisions for lung cancer.
引用
- Zhang X, He Y, Rao T, et al. Mining tumor and surrounding tissue information using artificial intelligence to predict responses to EGFR-targeted therapies and immunotherapy in lung cancer: a multicenter attribution analysis. Radiol Med. 2025. PMID: 41045354. doi:10.1007/s11547-025-02077-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。